ERC Synergy Grant

The aim is to provide support for a small group of two to four Principal Investigators to jointly addressambitious research problems that could not be addressed by the individual Principal Investigators and their teams working alone. Synergy projects should enable substantial advances at the … Read more à proposERC Synergy Grant

ERC Starting Grant

ERC Starting Grants are designed to support excellent Principal Investigators at the career stage at which they are starting their own independent research team or programme. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific … Read more à proposERC Starting Grant

AstraZeneca Challenge: Molecular Strategies to Minimize Off-Target Toxicities of Antibody Drug Conjugates

An antibody-drug conjugate (ADC) is comprised of an antibody connected to a cytotoxic agent with a linker. ADCs are designed to selectively target tumors via binding to specific markers found on the cell surface. Although many ADCs are in clinical development, only a few are FDA approved. To … Read more à proposAstraZeneca Challenge: Molecular Strategies to Minimize Off-Target Toxicities of Antibody Drug Conjugates

AstraZeneca Challenge: Improving the Targeting and Transduction Efficiency of Adeno-Associated Viral Vectors

Adeno-associated virus (AAV) is a non-enveloped virus that infects humans with no known pathogenicity. With the ability to infect both dividing and non-dividing cells, AAVs are being studied as promising vehicles for targeted gene therapy. Therefore, AstraZeneca desires innovative approaches to … Read more à proposAstraZeneca Challenge: Improving the Targeting and Transduction Efficiency of Adeno-Associated Viral Vectors